Xandar Kardian, a healthtech startup based in Toronto, has raised $10 million in Series A funding to develop contactless health monitoring solutions using digital radar signal processing.
The round was co-led by Phoenix Venture Partners, Portfolia Active Aging & Longevity Fund, and Taronga Ventures, with participation from other investors. This brings the total funding raised by the startup to $13.7 million. Zach Jonasson, Co-Founder and Managing General Partner of Phoenix Venture Partners, referred to the firm’s participation in the round by stating:
“We’re thrilled to partner with the Xandar Kardian team. Xandar Kardian’s groundbreaking technology and visionary team are well-positioned to enable truly frictionless and actionable health monitoring in healthcare facilities and at home.”
Xandar Kardian was founded in 2017 with the mission to improve safety and health while reducing costs for aging and other vulnerable populations. The startup is aiming to achieve this by deploying reliable and high-accuracy cleantech, smart building and healthcare solutions that make use of radar technology. Sam Yang, CEO and founder of Xandar Kardian, said in this regard:
“At Xandar Kardian, our goal is to enable predictive and preventive care for people everywhere by leveraging the advanced technologies available today. Our radar-based solutions are the future of healthcare and patient monitoring, allowing providers to take continuous vital sign measurements without any intervention – a true breakthrough that will save lives. The funds raised in this financing round will support the commercial rollout of our healthcare solutions and the expansion of our RealTech business in a digital-first era.”
By offering contact-free and continuous vital sign monitoring (VSM), Xandar Kardian believes it can revolutionize patient monitoring and at-home care, providing physicians and patients with important insights to predict health outcomes. The startup’s XK300 Autonomous Health Monitoring Solution has already been cleared by the U.S. Food & Drug Administration, which will allow the startup to
